NEW CLASS ADDED AT AMRITPEX 2023
Class 16: Azadi Ka Amrit Mahotsav (AKAM) is a newly added competitive class. The exhibits may cover all or any one or more themes of the AKAM – i.e., a) Freedom Struggle, b) Ideas@75, c) Resolve@75, d) Actions@75, and e) Achievements@75. Exhibits may be of 1, 2, 3, 4 or 5 frames (Maximum). No prequalification is required, and new exhibits are welcome. For more details, please visit https://amritpex2023.in/exhibitors/
Guidelines on AKAM Competitive Class
Class 16: Azadi Ka Amrit Mahotsav (AKAM) – Newly Added Competitive Class.
The participants can submit exhibits under AKAM competitive Class, as per details below: -
• The exhibits under this class will be judged by the Special Regulations for AKAM Class.
• All exhibitors under AKAM Class will get a Certificate of Participation and a Special Memento.
• In each AKAM theme 1st, 2nd and 3rd prize will also be given for Youth and Senior Classes.
• Award System for the AKAM class will be different from the regular Competition Classes.
• The exhibits may cover all or any one or more themes of the AKAM – i.e.,
a) Freedom Struggle,
b) Ideas@75,
c) Resolve@75,
d) Actions@75, and
e) Achievements@75
• Exhibits may be of 1, 2, 3, 4 or 5 frames (Maximum).
• No prequalification is required, and new exhibits are welcome.
• The exhibits in this Class will not be counted for the permitted number of the exhibits under Rule 3.10
• The Participants need to download the application form for AKAM Class available on AMRITPEX-2023 website (amritpex2023.in) under Register – Exhibitors and the duly filled form along with requisite enclosures will need to be sent on email id info@amritpex2023.in mentioning the Subject (Application form for Azadi ka Amrit Mahotsav Class) for consideration of their application in AMRITPEX-2023.
• Entry Fee: The participation fee is as under: –
a) Exhibitors (10 up to 21 years) is Rs.200/- per frame.
b) Exhibitors (21 years and above) is Rs.700/- per frame.
Payment to be made as per Rule 12.3 of AMRITPEX-2023 Prospectus.
No comments:
Post a Comment